Andrew Dunn is a biopharma correspondent at Endpoints News, focused on uncovering and explaining the future of the biotech and pharmaceutical industries. His reporting interests include the emerging role of AI in biotech, cell and gene therapy, and how money and medicine mix. He joined Endpoints in 2023 after previously covering the biotech industry at Business Insider and BioPharma Dive. His work has been cited by outlets like the Washington Post, CNN, and the New York Times, and I've appeared on CNBC, C-SPAN, and MSNBC to discuss my reporting.